EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy
December 15, 2025, 3:38 pm
Location: United Kingdom, England, Sheffield
Employees: 201-500
Founded date: 2014
Total raised: $8.95B
Location: Austria, Vienna
Employees: 1001-5000
Founded date: 1986
Total raised: $125M
EpilepsyGTx just raised $33 million. This Series A funding will fuel clinical trials. Their focus? A gene therapy for focal refractory epilepsy (FRE). FRE impacts millions globally. Current treatments often fail. EpilepsyGTx offers a potential one-time solution. It’s a significant step forward. The therapy, EPY201, targets the source of seizures. It uses localized delivery. This minimizes side effects. Investors include XGEN Venture and the British Business Bank. The goal is to improve patient lives. This funding unlocks a new era in epilepsy treatment.
---
EpilepsyGTx, a UK-based biotech firm, announced a $33 million Series A funding round. The investment will accelerate development of EPY201. EPY201 is a gene therapy for focal refractory epilepsy. This condition affects roughly 10 million people worldwide. Existing treatments provide limited relief.
The funding comes from XGEN Venture, the British Business Bank, and a major biopharmaceutical company. It will support Phase 1/2a clinical trials. These trials will assess EPY201’s safety and effectiveness. The therapy aims to provide seizure freedom. It’s a single-dose intervention. This contrasts sharply with current long-term medication regimens.
EPY201 utilizes an adeno-associated viral (AAV) vector. This delivers the therapeutic gene directly to the epileptogenic focus. This localized approach is crucial. It minimizes systemic exposure. Systemic exposure can cause unwanted side effects. Traditional gene therapies often face this challenge. EpilepsyGTx’s method avoids it.
The company previously secured $10 million in pre-seed and seed funding. This earlier investment came from the UCL Technology Fund and Zcube. This demonstrates continued investor confidence.
Focal epilepsy originates in a specific brain region. It becomes “refractory” when two or more medications fail. This leaves patients with limited options. Surgical resection and ablation are possibilities. However, these procedures carry risks. EPY201 offers a less invasive alternative.
The potential impact is substantial. Seizure control can dramatically improve quality of life. It can also reduce mortality risk. EpilepsyGTx aims to fundamentally change epilepsy treatment. They are building a pipeline of gene therapies. These therapies will target other neurological disorders. These disorders share the underlying issue of neuronal hyperexcitability.
EpilepsyGTx plans to leverage future funding. This will expand their research and development efforts. They will explore additional gene therapy candidates. The company is focused on durable, disease-modifying interventions. Localized gene delivery is central to their strategy.
The legal advisors for this deal were Taylor Wessing LLP and A&O Shearman. Panmure Liberum Cambridge Capital provided financial advisory services. This funding round positions EpilepsyGTx for significant growth. It also highlights the increasing investment in gene therapy. Gene therapy is emerging as a powerful tool. It’s transforming the treatment of neurological diseases. The company’s approach offers hope. It offers hope to patients with debilitating conditions. The clinical trials will be closely watched. They will determine the future of this promising therapy.
Keywords:
---
EpilepsyGTx, a UK-based biotech firm, announced a $33 million Series A funding round. The investment will accelerate development of EPY201. EPY201 is a gene therapy for focal refractory epilepsy. This condition affects roughly 10 million people worldwide. Existing treatments provide limited relief.
The funding comes from XGEN Venture, the British Business Bank, and a major biopharmaceutical company. It will support Phase 1/2a clinical trials. These trials will assess EPY201’s safety and effectiveness. The therapy aims to provide seizure freedom. It’s a single-dose intervention. This contrasts sharply with current long-term medication regimens.
Localized Delivery: A Key Advantage
EPY201 utilizes an adeno-associated viral (AAV) vector. This delivers the therapeutic gene directly to the epileptogenic focus. This localized approach is crucial. It minimizes systemic exposure. Systemic exposure can cause unwanted side effects. Traditional gene therapies often face this challenge. EpilepsyGTx’s method avoids it.
The company previously secured $10 million in pre-seed and seed funding. This earlier investment came from the UCL Technology Fund and Zcube. This demonstrates continued investor confidence.
Addressing a Critical Unmet Need
Focal epilepsy originates in a specific brain region. It becomes “refractory” when two or more medications fail. This leaves patients with limited options. Surgical resection and ablation are possibilities. However, these procedures carry risks. EPY201 offers a less invasive alternative.
The potential impact is substantial. Seizure control can dramatically improve quality of life. It can also reduce mortality risk. EpilepsyGTx aims to fundamentally change epilepsy treatment. They are building a pipeline of gene therapies. These therapies will target other neurological disorders. These disorders share the underlying issue of neuronal hyperexcitability.
Future Outlook
EpilepsyGTx plans to leverage future funding. This will expand their research and development efforts. They will explore additional gene therapy candidates. The company is focused on durable, disease-modifying interventions. Localized gene delivery is central to their strategy.
The legal advisors for this deal were Taylor Wessing LLP and A&O Shearman. Panmure Liberum Cambridge Capital provided financial advisory services. This funding round positions EpilepsyGTx for significant growth. It also highlights the increasing investment in gene therapy. Gene therapy is emerging as a powerful tool. It’s transforming the treatment of neurological diseases. The company’s approach offers hope. It offers hope to patients with debilitating conditions. The clinical trials will be closely watched. They will determine the future of this promising therapy.